Targeted Treatment for Advanced Non-Small Cell Lung Cancer with Increased Copies of the MET Gene

Short Title: S1900J

Enrollment Status: Recruiting

NCT #: NCT06116682

Specialty Area: Oncology

Condition Studied: Advanced Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out if amivantamab can help slow or stop the growth of lung cancer in people whose tumors have extra copies of the MET gene.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with advanced Non-Small Cell Lung Cancer (NSCLC) with extra copies of the MET gene (MET amplification)
Must be eligible to receive targeted therapy

What's Involved

Participation in the study will include:

Treatment with amivantamab given as an injection under the skin
CT scans and MRI to monitor response to treatment
Blood and tissue sample collection to monitor your health and treatment effects
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06116682

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews